JP7526673B2 - がんを治療するためのｈｐｋ１阻害剤としてのｎ－（フェニル）－２－（フェニル）ピリミジン－４－カルボキサミド誘導体及び関連化合物 - Google Patents
がんを治療するためのｈｐｋ１阻害剤としてのｎ－（フェニル）－２－（フェニル）ピリミジン－４－カルボキサミド誘導体及び関連化合物 Download PDFInfo
- Publication number
- JP7526673B2 JP7526673B2 JP2020566534A JP2020566534A JP7526673B2 JP 7526673 B2 JP7526673 B2 JP 7526673B2 JP 2020566534 A JP2020566534 A JP 2020566534A JP 2020566534 A JP2020566534 A JP 2020566534A JP 7526673 B2 JP7526673 B2 JP 7526673B2
- Authority
- JP
- Japan
- Prior art keywords
- independently selected
- alkyl
- membered heterocycloalkyl
- optionally substituted
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims description 136
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 title claims description 25
- 206010028980 Neoplasm Diseases 0.000 title claims description 7
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 title claims description 5
- 201000011510 cancer Diseases 0.000 title claims description 5
- XVLYIDSQDWSVHR-UHFFFAOYSA-N N,2-diphenylpyrimidine-4-carboxamide Chemical class C1(=CC=CC=C1)NC(=O)C1=NC(=NC=C1)C1=CC=CC=C1 XVLYIDSQDWSVHR-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims description 927
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 524
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 522
- 125000001424 substituent group Chemical group 0.000 claims description 507
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 500
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 494
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 451
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 386
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 377
- 125000003118 aryl group Chemical group 0.000 claims description 368
- 125000002947 alkylene group Chemical group 0.000 claims description 346
- 229910052799 carbon Inorganic materials 0.000 claims description 271
- 229910052739 hydrogen Inorganic materials 0.000 claims description 248
- -1 aminosulfonylamino Chemical group 0.000 claims description 243
- 125000005843 halogen group Chemical group 0.000 claims description 194
- 125000004429 atom Chemical group 0.000 claims description 123
- 150000003839 salts Chemical class 0.000 claims description 119
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 111
- 229910052717 sulfur Inorganic materials 0.000 claims description 93
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 80
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 80
- 125000003545 alkoxy group Chemical group 0.000 claims description 79
- 125000004432 carbon atom Chemical group C* 0.000 claims description 76
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 claims description 75
- 229910052805 deuterium Inorganic materials 0.000 claims description 69
- 229910052760 oxygen Inorganic materials 0.000 claims description 65
- 125000005842 heteroatom Chemical group 0.000 claims description 64
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 58
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 55
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 52
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 47
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 47
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 45
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 40
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 40
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims description 36
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 26
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 12
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims description 10
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 101000869592 Daucus carota Major allergen Dau c 1 Proteins 0.000 claims description 7
- 101000650136 Homo sapiens WAS/WASL-interacting protein family member 3 Proteins 0.000 claims description 7
- 102100027539 WAS/WASL-interacting protein family member 3 Human genes 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 5
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims description 5
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims description 5
- 125000005983 2,5-diazabicyclo[2.2.1]heptan-2-yl group Chemical group 0.000 claims description 5
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 5
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 claims description 5
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 5
- 229910052701 rubidium Inorganic materials 0.000 claims description 5
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000006311 cyclobutyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- AASCKKABVVRGPP-UHFFFAOYSA-N 2-(2-fluoro-6-methoxyphenyl)-N-(2-piperidin-4-ylphenyl)pyrimidine-4-carboxamide Chemical compound FC1=C(C(=CC=C1)OC)C1=NC=CC(=N1)C(=O)NC1=C(C=CC=C1)C1CCNCC1 AASCKKABVVRGPP-UHFFFAOYSA-N 0.000 claims description 2
- NMDDKDJYFSZOAT-UHFFFAOYSA-N 2-(2-fluoro-6-methoxyphenyl)-N-[5-fluoro-2-(2-pyridin-2-ylpyrrolidin-1-yl)phenyl]pyrimidine-4-carboxamide Chemical compound FC=1C=CC(=C(C=1)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)N1C(CCC1)C1=NC=CC=C1 NMDDKDJYFSZOAT-UHFFFAOYSA-N 0.000 claims description 2
- LEIMWMGQPLLTEJ-CQSZACIVSA-N 2-(2-fluoro-6-methoxyphenyl)-N-[5-fluoro-2-[(2R)-2-methylpiperazin-1-yl]phenyl]pyrimidine-4-carboxamide Chemical compound C1=C(F)C=CC(=C1NC(=O)C1=CC=NC(=N1)C1=C(F)C=CC=C1OC)N1[C@@H](CNCC1)C LEIMWMGQPLLTEJ-CQSZACIVSA-N 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- RNXDYGITDFPZQI-TYKWCNGQSA-N C=1(C(=NN(C=1C)C)C)C1=CC=C(NC(=O)C2=CC=NC(=N2)C2=C(OC)C=CC=C2F)C([C@H]2CC[C@@H](N)CC2)=C1 Chemical compound C=1(C(=NN(C=1C)C)C)C1=CC=C(NC(=O)C2=CC=NC(=N2)C2=C(OC)C=CC=C2F)C([C@H]2CC[C@@H](N)CC2)=C1 RNXDYGITDFPZQI-TYKWCNGQSA-N 0.000 claims description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- CICYHHIRLJBKTE-UHFFFAOYSA-N N-[2-(3,3a,4,5,6,6a-hexahydro-2H-pyrrolo[2,3-c]pyrrol-1-yl)-5-fluorophenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COC1=CC=CC(F)=C1C1=NC(=CC=N1)C(=O)NC1=C(C=CC(F)=C1)N1CCC2CNCC12 CICYHHIRLJBKTE-UHFFFAOYSA-N 0.000 claims description 2
- GQAGJQNVOPGUCQ-UHFFFAOYSA-N N-[2-(3-aminocyclohexyl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N(C1=C(C2CC(CCC2)N)C=CC=C1)C(=O)C1=CC=NC(=N1)C1=C(OC)C=CC=C1F GQAGJQNVOPGUCQ-UHFFFAOYSA-N 0.000 claims description 2
- LLFCXYBVJBKXHH-UHFFFAOYSA-N N-[2-(3-aminocyclopentyl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N(C1=C(C2CCC(N)C2)C=CC=C1)C(=O)C1=CC=NC(=N1)C1=C(OC)C=CC=C1F LLFCXYBVJBKXHH-UHFFFAOYSA-N 0.000 claims description 2
- WTMHDVVBBKONHX-HZPDHXFCSA-N N-[2-[(1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-(hydroxymethyl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound [C@H]12N(C[C@H](NC1)C2)C1=C(C=C(C=C1)CO)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F WTMHDVVBBKONHX-HZPDHXFCSA-N 0.000 claims description 2
- KDAAWCZNTXBHPP-QZTJIDSGSA-N N-[2-[(1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-fluoro-3-(1-methylpyrazol-4-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound [C@H]12N(C[C@H](NC1)C2)C1=C(C=C(C=C1C=1C=NN(C=1)C)F)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F KDAAWCZNTXBHPP-QZTJIDSGSA-N 0.000 claims description 2
- YOVUFANMIRCCQZ-RTBURBONSA-N N-[2-[(1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-fluoro-3-pyridin-3-ylphenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound [C@H]12N(C[C@H](NC1)C2)C1=C(C=C(C=C1C=1C=NC=CC=1)F)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F YOVUFANMIRCCQZ-RTBURBONSA-N 0.000 claims description 2
- JKHBVOCOHYSWTQ-HUUCEWRRSA-N N-[2-[(1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-fluorophenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound [C@H]12N(C[C@H](NC1)C2)C1=C(C=C(C=C1)F)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F JKHBVOCOHYSWTQ-HUUCEWRRSA-N 0.000 claims description 2
- UTYUODSGWVOIFI-HUUCEWRRSA-N N-[2-[(1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-methoxyphenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound [C@H]12N(C[C@H](NC1)C2)C1=C(C=C(C=C1)OC)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F UTYUODSGWVOIFI-HUUCEWRRSA-N 0.000 claims description 2
- VFYLBKWAGCOTCH-IAGOWNOFSA-N N-[2-[(1R,4R)-5-ethyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-fluorophenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C(C)N1[C@H]2CN([C@@H](C1)C2)C1=C(C=C(C=C1)F)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F VFYLBKWAGCOTCH-IAGOWNOFSA-N 0.000 claims description 2
- QIDMUDUZDJKNEX-PMACEKPBSA-N N-[2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-(1,3,5-trimethylpyrazol-4-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COc1cccc(F)c1-c1nccc(n1)C(=O)Nc1ccc(cc1N1C[C@@H]2C[C@H]1CN2)-c1c(C)nn(C)c1C QIDMUDUZDJKNEX-PMACEKPBSA-N 0.000 claims description 2
- VCZPJHYQIPIKSV-PMACEKPBSA-N N-[2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-(2-methylpyridin-3-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COc1cccc(F)c1-c1nccc(n1)C(=O)Nc1ccc(cc1N1C[C@@H]2C[C@H]1CN2)-c1cccnc1C VCZPJHYQIPIKSV-PMACEKPBSA-N 0.000 claims description 2
- DSDYWUYEEWMDFK-OALUTQOASA-N N-[2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-(4-methoxypyridin-3-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COc1ccncc1-c1ccc(NC(=O)c2ccnc(n2)-c2c(F)cccc2OC)c(c1)N1C[C@@H]2C[C@H]1CN2 DSDYWUYEEWMDFK-OALUTQOASA-N 0.000 claims description 2
- JEHNXRAWWCPZSM-IHPCNDPISA-N N-[2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-[(2S)-2-(methoxymethyl)azetidin-1-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COC[C@@H]1CCN1c1ccc(NC(=O)c2ccnc(n2)-c2c(F)cccc2OC)c(c1)N1C[C@@H]2C[C@H]1CN2 JEHNXRAWWCPZSM-IHPCNDPISA-N 0.000 claims description 2
- UZLJNVXUUAUUCL-ROUUACIJSA-N N-[2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-fluoro-4-(1-methyl-6-oxopyridin-3-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COc1cccc(F)c1-c1nccc(n1)C(=O)Nc1cc(F)c(cc1N1C[C@@H]2C[C@H]1CN2)-c1ccc(=O)n(C)c1 UZLJNVXUUAUUCL-ROUUACIJSA-N 0.000 claims description 2
- IVCZPZNMHCJCCD-IRXDYDNUSA-N N-[2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-fluoro-4-(1-methylpyrazol-4-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COc1cccc(F)c1-c1nccc(n1)C(=O)Nc1cc(F)c(cc1N1C[C@@H]2C[C@H]1CN2)-c1cnn(C)c1 IVCZPZNMHCJCCD-IRXDYDNUSA-N 0.000 claims description 2
- JBFWLYUTIKICBY-ROUUACIJSA-N N-[2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-fluoro-4-(2-methylpyridin-3-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COc1cccc(F)c1-c1nccc(n1)C(=O)Nc1cc(F)c(cc1N1C[C@@H]2C[C@H]1CN2)-c1cccnc1C JBFWLYUTIKICBY-ROUUACIJSA-N 0.000 claims description 2
- UIXZBVNKVGAKSX-GJZGRUSLSA-N N-[2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-fluoro-4-(hydroxymethyl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COc1cccc(F)c1-c1nccc(n1)C(=O)Nc1cc(F)c(CO)cc1N1C[C@@H]2C[C@H]1CN2 UIXZBVNKVGAKSX-GJZGRUSLSA-N 0.000 claims description 2
- YVDUQPDPKGEWFB-OALUTQOASA-N N-[2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-fluoro-4-(morpholin-4-ylmethyl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COc1cccc(F)c1-c1nccc(n1)C(=O)Nc1cc(F)c(CN2CCOCC2)cc1N1C[C@@H]2C[C@H]1CN2 YVDUQPDPKGEWFB-OALUTQOASA-N 0.000 claims description 2
- YVSYOIRMGSWDKV-OALUTQOASA-N N-[2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-fluoro-4-[6-(hydroxymethyl)pyridin-3-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COc1cccc(F)c1-c1nccc(n1)C(=O)Nc1cc(F)c(cc1N1C[C@@H]2C[C@H]1CN2)-c1ccc(CO)nc1 YVSYOIRMGSWDKV-OALUTQOASA-N 0.000 claims description 2
- CDXQAYIDSWLSDP-ROUUACIJSA-N N-[2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-fluoro-4-[6-(methylcarbamoyl)pyridin-3-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound CNC(=O)c1ccc(cn1)-c1cc(N2C[C@@H]3C[C@H]2CN3)c(NC(=O)c2ccnc(n2)-c2c(F)cccc2OC)cc1F CDXQAYIDSWLSDP-ROUUACIJSA-N 0.000 claims description 2
- DDNGJFFPOPCHAZ-IRXDYDNUSA-N N-[2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-fluoro-4-morpholin-4-ylphenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COc1cccc(F)c1-c1nccc(n1)C(=O)Nc1cc(F)c(cc1N1C[C@@H]2C[C@H]1CN2)N1CCOCC1 DDNGJFFPOPCHAZ-IRXDYDNUSA-N 0.000 claims description 2
- JJXNJDIRWJNGBX-OAHLLOKOSA-N N-[2-[(2R)-2-(aminomethyl)pyrrolidin-1-yl]-5-fluorophenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N(C1=C(N2CCC[C@@H]2CN)C=CC(F)=C1)C(=O)C1=CC=NC(=N1)C1=C(F)C=CC=C1OC JJXNJDIRWJNGBX-OAHLLOKOSA-N 0.000 claims description 2
- HGFPJAGQCIFATM-OAQYLSRUSA-N N-[2-[(2R)-2-(cyanomethyl)morpholin-4-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1(C=2C=NC=CC=2C#N)=CC=C(NC(=O)C2=CC=NC(=N2)C2=C(F)C=CC=C2OC)C(N2C[C@@H](CC#N)OCC2)=C1 HGFPJAGQCIFATM-OAQYLSRUSA-N 0.000 claims description 2
- NRYRSQRRSBLVER-IRXDYDNUSA-N N-[2-[(2S,4S)-4-(dimethylamino)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-fluorophenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1=C(F)C=CC(=C1NC(=O)C1=CC=NC(=N1)C1=C(F)C=CC=C1OC)N1C[C@@H](N(C)C)C[C@H]1CO NRYRSQRRSBLVER-IRXDYDNUSA-N 0.000 claims description 2
- WXKLVVXNBFIYSG-DCFHFQCYSA-N N-[2-[(2S,4S)-4-amino-2-(1-hydroxycyclopropyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)C1(CC1)O WXKLVVXNBFIYSG-DCFHFQCYSA-N 0.000 claims description 2
- YTYIKQGGIQKXKW-DCFHFQCYSA-N N-[2-[(2S,4S)-4-amino-2-(2-hydroxypropan-2-yl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)C(C)(C)O YTYIKQGGIQKXKW-DCFHFQCYSA-N 0.000 claims description 2
- WJEPQBUJWFNXPG-IRXDYDNUSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(1-cyanocyclopropyl)phenyl]-2-(2,6-difluorophenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C1(CC1)C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1F)F)CO WJEPQBUJWFNXPG-IRXDYDNUSA-N 0.000 claims description 2
- SXTCCWXLNUBUGV-PMACEKPBSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(2-cyano-6-fluorophenyl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound FC1=C(C2=CC=C(NC(=O)C3=CC=NC(=N3)C3=C(F)C=CC=C3OC)C(N3C[C@@H](N)C[C@H]3CO)=C2)C(C#N)=CC=C1 SXTCCWXLNUBUGV-PMACEKPBSA-N 0.000 claims description 2
- BLLJUCXNHUVEHL-PMACEKPBSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(2-methylpyridin-3-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C=1(C=CC=NC=1C)C1=CC=C(NC(=O)C2=CC=NC(=N2)C2=C(F)C=CC=C2OC)C(N2C[C@@H](N)C[C@H]2CO)=C1 BLLJUCXNHUVEHL-PMACEKPBSA-N 0.000 claims description 2
- HENRITOGWFFGGA-PMACEKPBSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(3-cyanopyridin-2-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C1=NC=CC=C1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)CO HENRITOGWFFGGA-PMACEKPBSA-N 0.000 claims description 2
- MRLPZQXQFOPDDQ-PMACEKPBSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(3-cyanopyridin-4-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C1=C(C=NC=C1)C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)CO MRLPZQXQFOPDDQ-PMACEKPBSA-N 0.000 claims description 2
- ZMSBSUWREUXWEU-OALUTQOASA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(3-methoxypyridin-4-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1(C=2C(OC)=CN=CC=2)=CC=C(NC(=O)C2=CC=NC(=N2)C2=C(F)C=CC=C2OC)C(N2[C@@H](C[C@H](N)C2)CO)=C1 ZMSBSUWREUXWEU-OALUTQOASA-N 0.000 claims description 2
- WAWDCCVZPCGIJC-OALUTQOASA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyano-2-methylpyrazol-3-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1(=C(C=NN1C)C#N)C1=CC=C(NC(=O)C2=CC=NC(=N2)C2=C(F)C=CC=C2OC)C(N2[C@@H](C[C@H](N)C2)CO)=C1 WAWDCCVZPCGIJC-OALUTQOASA-N 0.000 claims description 2
- SEKQICVALVTKMV-OALUTQOASA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-(2,3-difluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1(C#N)=C(C2=CC=C(NC(=O)C3=CC=NC(=N3)C3=C(OC)C=CC(F)=C3F)C(N3C[C@@H](N)C[C@H]3CO)=C2)C=NC=C1 SEKQICVALVTKMV-OALUTQOASA-N 0.000 claims description 2
- LDCDYMPNMGJUDB-OALUTQOASA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-(2,6-difluorophenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1F)F)CO LDCDYMPNMGJUDB-OALUTQOASA-N 0.000 claims description 2
- PJPVNRZDRDNSLL-OALUTQOASA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-(2-chloro-6-fluorophenyl)pyrimidine-4-carboxamide Chemical compound C1(C#N)=C(C2=CC=C(NC(=O)C3=CC=NC(=N3)C3=C(Cl)C=CC=C3F)C(N3C[C@@H](N)C[C@H]3CO)=C2)C=NC=C1 PJPVNRZDRDNSLL-OALUTQOASA-N 0.000 claims description 2
- KZPWAZPBJQZJGY-VXKWHMMOSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-(2-cyclopropyl-6-fluorophenyl)pyrimidine-4-carboxamide Chemical compound C=1(C=NC=CC=1C#N)C1=CC=C(NC(=O)C2=CC=NC(=N2)C2=C(C3CC3)C=CC=C2F)C(N2C[C@@H](N)C[C@H]2CO)=C1 KZPWAZPBJQZJGY-VXKWHMMOSA-N 0.000 claims description 2
- RQXLMBLSWQYUNA-SFTDATJTSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-(2-ethoxy-6-fluorophenyl)pyrimidine-4-carboxamide Chemical compound C=1(C=NC=CC=1C#N)C1=CC=C(NC(=O)C2=CC=NC(=N2)C2=C(OCC)C=CC=C2F)C(N2[C@H](CO)C[C@H](N)C2)=C1 RQXLMBLSWQYUNA-SFTDATJTSA-N 0.000 claims description 2
- BZUQIMZNTIMOAJ-SFTDATJTSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-(2-fluoro-6-methoxy-4-methylphenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=C(C=C1OC)C)F)CO BZUQIMZNTIMOAJ-SFTDATJTSA-N 0.000 claims description 2
- XCAXLCSQKKQKHA-PMACEKPBSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)CO XCAXLCSQKKQKHA-PMACEKPBSA-N 0.000 claims description 2
- SOVOQANEIZCLPU-SFTDATJTSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-(2-fluoro-6-methylphenyl)pyrimidine-4-carboxamide Chemical compound C(#N)C1=C(C2=CC=C(NC(=O)C3=CC=NC(=N3)C3=C(C)C=CC=C3F)C(N3[C@@H](C[C@H](N)C3)CO)=C2)C=NC=C1 SOVOQANEIZCLPU-SFTDATJTSA-N 0.000 claims description 2
- YAOFYZWYGQFFGQ-OALUTQOASA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-(3,6-difluoro-2-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1(C#N)=C(C2=CC=C(NC(=O)C3=CC=NC(=N3)C3=C(OC)C(F)=CC=C3F)C(N3C[C@@H](N)C[C@H]3CO)=C2)C=NC=C1 YAOFYZWYGQFFGQ-OALUTQOASA-N 0.000 claims description 2
- GNAQOVDYXBQJML-PMACEKPBSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-(3,6-difluoro-2-methylphenyl)pyrimidine-4-carboxamide Chemical compound C(#N)C1=C(C2=CC=C(NC(=O)C3=CC=NC(=N3)C3=C(C)C(F)=CC=C3F)C(N3[C@@H](C[C@H](N)C3)CO)=C2)C=NC=C1 GNAQOVDYXBQJML-PMACEKPBSA-N 0.000 claims description 2
- SEKQICVALVTKMV-LAYNNCTGSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-[2,3-difluoro-6-(trideuteriomethoxy)phenyl]pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C(=CC=C1OC([2H])([2H])[2H])F)F)CO SEKQICVALVTKMV-LAYNNCTGSA-N 0.000 claims description 2
- FMVORWLTJBNIRP-OALUTQOASA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-[2-(difluoromethoxy)-6-fluorophenyl]pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1F)OC(F)F)CO FMVORWLTJBNIRP-OALUTQOASA-N 0.000 claims description 2
- XCAXLCSQKKQKHA-HIXAKMJBSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-[2-fluoro-6-(trideuteriomethoxy)phenyl]pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC([2H])([2H])[2H])F)CO XCAXLCSQKKQKHA-HIXAKMJBSA-N 0.000 claims description 2
- YAOFYZWYGQFFGQ-LAYNNCTGSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-[3,6-difluoro-2-(trideuteriomethoxy)phenyl]pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C(=CC=C1F)F)OC([2H])([2H])[2H])CO YAOFYZWYGQFFGQ-LAYNNCTGSA-N 0.000 claims description 2
- OBXZCGSMSIDKGN-JDNSAJSRSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-[3-cyano-2-fluoro-6-(trideuteriomethoxy)phenyl]pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C(=CC=C1OC([2H])([2H])[2H])C#N)F)CO OBXZCGSMSIDKGN-JDNSAJSRSA-N 0.000 claims description 2
- XCAXLCSQKKQKHA-QJPPTZNUSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-[3-deuterio-6-fluoro-2-(trideuteriomethoxy)phenyl]pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC(=C1OC([2H])([2H])[2H])[2H])F)CO XCAXLCSQKKQKHA-QJPPTZNUSA-N 0.000 claims description 2
- XBYPJFSNPXFDIH-VXKWHMMOSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-5-cyano-6-(2-fluoro-6-methoxyphenyl)pyridine-2-carboxamide Chemical compound C1(C#N)=C(C2=CC=C(NC(=O)C3=CC=C(C#N)C(C4=C(F)C=CC=C4OC)=N3)C(N3C[C@@H](N)C[C@H]3CO)=C2)C=NC=C1 XBYPJFSNPXFDIH-VXKWHMMOSA-N 0.000 claims description 2
- SAERCLLLTAZHHL-SFTDATJTSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-6-(2-fluoro-6-methoxyphenyl)-5-methoxypyridine-2-carboxamide Chemical compound C1(C#N)=C(C2=CC=C(NC(=O)C3=CC=C(OC)C(C4=C(F)C=CC=C4OC)=N3)C(N3[C@@H](C[C@H](N)C3)CO)=C2)C=NC=C1 SAERCLLLTAZHHL-SFTDATJTSA-N 0.000 claims description 2
- WWTQVAUFPQCPKO-SFTDATJTSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-6-(2-fluoro-6-methoxyphenyl)pyridine-2-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(C1=NC(=CC=C1)C1=C(C=CC=C1OC)F)=O)CO WWTQVAUFPQCPKO-SFTDATJTSA-N 0.000 claims description 2
- CHVFUQSUXYNPPR-VXKWHMMOSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(5-cyano-2-pyrrolidin-1-ylpyridin-4-yl)phenyl]-2-(2,6-difluorophenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C1=CC(=NC=C1C#N)N1CCCC1)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1F)F)CO CHVFUQSUXYNPPR-VXKWHMMOSA-N 0.000 claims description 2
- UBLUXQFTLMTYLO-PMACEKPBSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-(oxan-4-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1C(C2=CC(=C(C=C2)NC(=O)C2=CC=NC(=N2)C2=C(F)C=CC=C2OC)N2C[C@@H](N)C[C@H]2CO)CCOC1 UBLUXQFTLMTYLO-PMACEKPBSA-N 0.000 claims description 2
- LYYVVXSDOBKXQQ-GJZGRUSLSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-chlorophenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1(=CC=C(C=C1N1[C@@H](C[C@H](N)C1)CO)Cl)NC(=O)C1=CC=NC(=N1)C1=C(OC)C=CC=C1F LYYVVXSDOBKXQQ-GJZGRUSLSA-N 0.000 claims description 2
- ATUJAUVLSRXUKR-GJZGRUSLSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-fluorophenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1(=CC=C(C=C1N1[C@@H](C[C@H](N)C1)CO)F)NC(=O)C1=CC=NC(=N1)C1=C(OC)C=CC=C1F ATUJAUVLSRXUKR-GJZGRUSLSA-N 0.000 claims description 2
- IOHPKJPPERILGU-GJZGRUSLSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-methylsulfonylphenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)S(=O)(=O)C)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)CO IOHPKJPPERILGU-GJZGRUSLSA-N 0.000 claims description 2
- BJCGXALNCRGPBG-ROUUACIJSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-4-propan-2-ylphenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C(C)C)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)CO BJCGXALNCRGPBG-ROUUACIJSA-N 0.000 claims description 2
- NDNBINPLTHGVKS-KBPBESRZSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-5-fluorophenyl]-2-(2,3-difluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1=C(C=CC(=C1NC(=O)C1=CC=NC(=N1)C1=C(OC)C=CC(F)=C1F)N1C[C@@H](N)C[C@H]1CO)F NDNBINPLTHGVKS-KBPBESRZSA-N 0.000 claims description 2
- AJBJISUUCJXQBM-KBPBESRZSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-5-fluorophenyl]-2-(2,6-difluorophenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=C(C=C1)F)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1F)F)CO AJBJISUUCJXQBM-KBPBESRZSA-N 0.000 claims description 2
- SUBYPZBREZXPCW-GJZGRUSLSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-5-fluorophenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=C(C=C1)F)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)CO SUBYPZBREZXPCW-GJZGRUSLSA-N 0.000 claims description 2
- VCJUDPLLCXBMCM-HOTGVXAUSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-5-fluorophenyl]-2-(3-cyano-2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=C(C=C1)F)NC(=O)C1=NC(=NC=C1)C1=C(C(=CC=C1OC)C#N)F)CO VCJUDPLLCXBMCM-HOTGVXAUSA-N 0.000 claims description 2
- NQUIPSPVQHBWOM-LYDMTYCISA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-5-fluorophenyl]-2-[2-fluoro-3-methyl-6-(trideuteriomethoxy)phenyl]pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=C(C=C1)F)NC(=O)C1=NC(=NC=C1)C1=C(C(=CC=C1OC([2H])([2H])[2H])C)F)CO NQUIPSPVQHBWOM-LYDMTYCISA-N 0.000 claims description 2
- ADUXEIHMPHRMBP-HOTGVXAUSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylphenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1(=CC(=CC=C1N1C[C@@H](N)C[C@H]1CO)C)NC(=O)C1=CC=NC(=N1)C1=C(F)C=CC=C1OC ADUXEIHMPHRMBP-HOTGVXAUSA-N 0.000 claims description 2
- NSYCWQABINWBNU-ROUUACIJSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]-6-(1,3,5-trimethylpyrazol-4-yl)pyridin-3-yl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=NC(=CC=C1NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)C=1C(=NN(C=1C)C)C)CO NSYCWQABINWBNU-ROUUACIJSA-N 0.000 claims description 2
- FEHHLVAMJBTESK-GJZGRUSLSA-N N-[2-[(2S,4S)-4-amino-2-(hydroxymethyl)pyrrolidin-1-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC=C1)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)CO FEHHLVAMJBTESK-GJZGRUSLSA-N 0.000 claims description 2
- XCAXLCSQKKQKHA-PVPQDCENSA-N N-[2-[(2S,4S)-4-amino-2-[dideuterio(hydroxy)methyl]pyrrolidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N[C@H]1C[C@H](N(C1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)C([2H])([2H])O XCAXLCSQKKQKHA-PVPQDCENSA-N 0.000 claims description 2
- ZXFVDANYDFDDRY-RXVVDRJESA-N N-[2-[(2S,4S)-4-amino-2-methylpiperidin-1-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N[C@@H]1C[C@@H](N(CC1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)C ZXFVDANYDFDDRY-RXVVDRJESA-N 0.000 claims description 2
- PZWKQEQSYRXWEJ-AWEZNQCLSA-N N-[2-[(3S)-3-aminopyrrolidin-1-yl]-5-fluorophenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1=C(C=CC(=C1NC(=O)C1=CC=NC(=N1)C1=C(F)C=CC=C1OC)N1C[C@@H](N)CC1)F PZWKQEQSYRXWEJ-AWEZNQCLSA-N 0.000 claims description 2
- JZPWBAMLOBMQQB-HXUWFJFHSA-N N-[2-[(8aR)-3-oxo-5,6,8,8a-tetrahydro-1H-[1,3]oxazolo[3,4-a]pyrazin-7-yl]-4-(4-cyanopyridin-3-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C(#N)C1=C(C=NC=C1)C1=CC(=C(C=C1)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)N1C[C@H]2N(CC1)C(OC2)=O JZPWBAMLOBMQQB-HXUWFJFHSA-N 0.000 claims description 2
- YLUXKRMQCFVPCP-ZIAGYGMSSA-N N-[3-bromo-2-[(1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-fluorophenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound [C@H]12N(C[C@H](NC1)C2)C1=C(C=C(C=C1Br)F)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F YLUXKRMQCFVPCP-ZIAGYGMSSA-N 0.000 claims description 2
- LABQLLVGLJUGKJ-HZPDHXFCSA-N N-[3-cyano-2-[(1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound [C@H]12N(C[C@H](NC1)C2)C1=C(C=CC=C1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F LABQLLVGLJUGKJ-HZPDHXFCSA-N 0.000 claims description 2
- XYVBNQKFSKHJQS-ROUUACIJSA-N N-[4-(3-cyanopyridin-4-yl)-2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-3-fluorophenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COc1cccc(F)c1-c1nccc(n1)C(=O)Nc1ccc(c(F)c1N1C[C@@H]2C[C@H]1CN2)-c1ccncc1C#N XYVBNQKFSKHJQS-ROUUACIJSA-N 0.000 claims description 2
- IPHYANNUDKBFBD-PMACEKPBSA-N N-[4-(3-cyanopyridin-4-yl)-2-[(2S,4S)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C=1(C=CN=CC=1C#N)C1=CC=C(NC(=O)C2=CC=NC(=N2)C2=C(F)C=CC=C2OC)C(N2C[C@@H](O)C[C@H]2CO)=C1 IPHYANNUDKBFBD-PMACEKPBSA-N 0.000 claims description 2
- XDLMFXYMCXJTLV-UHFFFAOYSA-N N-[4-(4-cyanopyridin-3-yl)-2-(4-methylpiperazin-1-yl)phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C(#N)C1=C(C=NC=C1)C1=CC(=C(C=C1)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)N1CCN(CC1)C XDLMFXYMCXJTLV-UHFFFAOYSA-N 0.000 claims description 2
- IKKRRLFINVYTBM-YLORPAJWSA-N N-[4-(4-cyanopyridin-3-yl)-2-[(1S,3R,4S)-3-(hydroxymethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C(#N)C1=C(C=NC=C1)C1=CC(=C(C=C1)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)N1[C@@H]2CN[C@H]([C@@H]1CO)C2 IKKRRLFINVYTBM-YLORPAJWSA-N 0.000 claims description 2
- QLSPHCRQKIJNFU-WRGVRERRSA-N N-[4-(4-cyanopyridin-3-yl)-2-[(1S,4S)-1-(hydroxymethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C(#N)C1=C(C=NC=C1)C1=CC(=C(C=C1)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)N1[C@@]2(CN[C@H](C1)C2)CO QLSPHCRQKIJNFU-WRGVRERRSA-N 0.000 claims description 2
- XRORCPXIZILXNC-PMACEKPBSA-N N-[4-(4-cyanopyridin-3-yl)-2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COc1cccc(F)c1-c1nccc(n1)C(=O)Nc1ccc(cc1N1C[C@@H]2C[C@H]1CN2)-c1cnccc1C#N XRORCPXIZILXNC-PMACEKPBSA-N 0.000 claims description 2
- YQXNONOLWITCCE-BGOLNKOXSA-N N-[4-(4-cyanopyridin-3-yl)-2-[(1S,4S)-4-(hydroxymethyl)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C(#N)C1=C(C=NC=C1)C1=CC(=C(C=C1)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)N1[C@@H]2CN([C@](C1)(C2)CO)C YQXNONOLWITCCE-BGOLNKOXSA-N 0.000 claims description 2
- DYVFWWINLFAAQT-OAQYLSRUSA-N N-[4-(4-cyanopyridin-3-yl)-2-[(2R)-2-[(dimethylamino)methyl]azetidin-1-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1=C(C=C(C(=C1)NC(=O)C1=CC=NC(=N1)C1=C(F)C=CC=C1OC)N1CC[C@@H]1CN(C)C)C1=CN=CC=C1C#N DYVFWWINLFAAQT-OAQYLSRUSA-N 0.000 claims description 2
- NFWXCTFEDOTPOS-IBGZPJMESA-N N-[4-(4-cyanopyridin-3-yl)-2-[(2S)-2-(hydroxymethyl)azetidin-1-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1(C=2C=NC=CC=2C#N)=CC=C(NC(=O)C2=CC=NC(=N2)C2=C(F)C=CC=C2OC)C(N2CC[C@H]2CO)=C1 NFWXCTFEDOTPOS-IBGZPJMESA-N 0.000 claims description 2
- GIJBICQSKQXRAY-FQEVSTJZSA-N N-[4-(4-cyanopyridin-3-yl)-2-[(2S)-2-(hydroxymethyl)morpholin-4-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N#CC1=C(C2=CC=C(NC(=O)C3=CC=NC(=N3)C3=C(F)C=CC=C3OC)C(N3C[C@@H](CO)OCC3)=C2)C=NC=C1 GIJBICQSKQXRAY-FQEVSTJZSA-N 0.000 claims description 2
- QXYFMKJAPDFZAL-QFIPXVFZSA-N N-[4-(4-cyanopyridin-3-yl)-2-[(2S)-2-[(dimethylamino)methyl]morpholin-4-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C(#N)C1=C(C=NC=C1)C1=CC(=C(C=C1)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)N1C[C@@H](OCC1)CN(C)C QXYFMKJAPDFZAL-QFIPXVFZSA-N 0.000 claims description 2
- QWYZASZVCSXDCB-NQIIRXRSSA-N N-[4-(4-cyanopyridin-3-yl)-2-[(2S,5R)-2-(hydroxymethyl)-5-methylpiperazin-1-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C(#N)C1=C(C=NC=C1)C1=CC(=C(C=C1)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)N1[C@@H](CN[C@@H](C1)C)CO QWYZASZVCSXDCB-NQIIRXRSSA-N 0.000 claims description 2
- QWYZASZVCSXDCB-RXVVDRJESA-N N-[4-(4-cyanopyridin-3-yl)-2-[(2S,5S)-2-(hydroxymethyl)-5-methylpiperazin-1-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C(#N)C1=C(C2=CC=C(NC(=O)C3=CC=NC(=N3)C3=C(F)C=CC=C3OC)C(N3[C@@H](CN[C@H](C3)C)CO)=C2)C=NC=C1 QWYZASZVCSXDCB-RXVVDRJESA-N 0.000 claims description 2
- AEUIHHIOWGKVTM-NRFANRHFSA-N N-[4-(4-cyanopyridin-3-yl)-2-[(6S)-6-(hydroxymethyl)-4,7-diazaspiro[2.5]octan-7-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1(C#N)=C(C2=CC=C(NC(=O)C3=CC=NC(=N3)C3=C(F)C=CC=C3OC)C(N3[C@@H](CNC4(C3)CC4)CO)=C2)C=NC=C1 AEUIHHIOWGKVTM-NRFANRHFSA-N 0.000 claims description 2
- SMOFRAIZAKBEKX-UHFFFAOYSA-N N-[4-(4-cyanopyridin-3-yl)-2-[3-(methoxymethyl)azetidin-1-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1=C(C=C(C(NC(=O)C2=CC=NC(=N2)C2=C(F)C=CC=C2OC)=C1)N1CC(COC)C1)C1=CN=CC=C1C#N SMOFRAIZAKBEKX-UHFFFAOYSA-N 0.000 claims description 2
- RFRULRQBRDHJSB-UHFFFAOYSA-N N-[4-(4-cyanopyridin-3-yl)-2-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1=C(C=C(C(=C1)NC(=O)C1=CC=NC(=N1)C1=C(F)C=CC=C1OC)N1CCN(CC1)CCO)C1=CN=CC=C1C#N RFRULRQBRDHJSB-UHFFFAOYSA-N 0.000 claims description 2
- ASQRDBRAOIOVCV-WMZOPIPTSA-N N-[4-(azetidin-1-yl)-2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound N1(CCC1)C1=CC(=C(C=C1)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)N1[C@@H]2CN[C@H](C1)C2 ASQRDBRAOIOVCV-WMZOPIPTSA-N 0.000 claims description 2
- QBKVMDTUGKFMFU-OALUTQOASA-N N-[4-[(cyclobutylamino)methyl]-2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-fluorophenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COc1cccc(F)c1-c1nccc(n1)C(=O)Nc1cc(F)c(CNC2CCC2)cc1N1C[C@@H]2C[C@H]1CN2 QBKVMDTUGKFMFU-OALUTQOASA-N 0.000 claims description 2
- PCYDUWDMJRORMQ-STQMWFEESA-N N-[4-bromo-2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-5-fluorophenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COc1cccc(F)c1-c1nccc(n1)C(=O)Nc1cc(F)c(Br)cc1N1C[C@@H]2C[C@H]1CN2 PCYDUWDMJRORMQ-STQMWFEESA-N 0.000 claims description 2
- GCSAIPWEYFAKIV-HZPDHXFCSA-N N-[5-cyano-2-[(1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound [C@H]12N(C[C@H](NC1)C2)C1=C(C=C(C=C1)C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F GCSAIPWEYFAKIV-HZPDHXFCSA-N 0.000 claims description 2
- KHDDAKVJAWLZOV-IAGOWNOFSA-N N-[5-fluoro-2-[(1R,4R)-5-(2-hydroxyethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound FC=1C=CC(=C(C=1)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)N1[C@H]2CN([C@@H](C1)C2)CCO KHDDAKVJAWLZOV-IAGOWNOFSA-N 0.000 claims description 2
- KWFNRFXZHFURGM-OAHLLOKOSA-N N-[5-fluoro-2-[(2R)-2-(hydroxymethyl)piperazin-1-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1=C(F)C=CC(=C1NC(=O)C1=CC=NC(=N1)C1=C(F)C=CC=C1OC)N1CCNC[C@@H]1CO KWFNRFXZHFURGM-OAHLLOKOSA-N 0.000 claims description 2
- QKZQZKCJWCHGHH-OAHLLOKOSA-N N-[5-fluoro-2-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1=C(F)C=CC(=C1NC(=O)C1=CC=NC(=N1)C1=C(F)C=CC=C1OC)N1[C@H](CCC1)CO QKZQZKCJWCHGHH-OAHLLOKOSA-N 0.000 claims description 2
- PBRXEKAVOHWRAQ-MRXNPFEDSA-N N-[5-fluoro-2-[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1=C(F)C=CC(=C1NC(=O)C1=CC=NC(=N1)C1=C(F)C=CC=C1OC)N1[C@H](CCC1)COC PBRXEKAVOHWRAQ-MRXNPFEDSA-N 0.000 claims description 2
- KAHMPNUNDKTEOW-ROUUACIJSA-N N-[5-fluoro-2-[(2S,4S)-2-(hydroxymethyl)-4-(propan-2-ylamino)pyrrolidin-1-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1=C(F)C=CC(=C1NC(=O)C1=CC=NC(=N1)C1=C(F)C=CC=C1OC)N1C[C@@H](NC(C)C)C[C@H]1CO KAHMPNUNDKTEOW-ROUUACIJSA-N 0.000 claims description 2
- JOXBUECBAXTYRH-ZFWWWQNUSA-N N-[5-fluoro-2-[(2S,4S)-4-hydroxy-2-methylpyrrolidin-1-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1=C(C=CC(=C1NC(=O)C1=CC=NC(=N1)C1=C(F)C=CC=C1OC)N1C[C@@H](O)C[C@@H]1C)F JOXBUECBAXTYRH-ZFWWWQNUSA-N 0.000 claims description 2
- BMOHPMIYUFXSQJ-INIZCTEOSA-N N-[5-fluoro-2-[(3S)-3-(hydroxymethyl)piperazin-1-yl]-4-propan-2-ylphenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound FC=1C(=CC(=C(C=1)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F)N1C[C@H](NCC1)CO)C(C)C BMOHPMIYUFXSQJ-INIZCTEOSA-N 0.000 claims description 2
- YBFBZHKVFCRAFM-HNNXBMFYSA-N N-[5-fluoro-2-[(3S)-3-(hydroxymethyl)piperazin-1-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1=C(C=CC(=C1NC(=O)C1=CC=NC(=N1)C1=C(F)C=CC=C1OC)N1C[C@@H](CO)NCC1)F YBFBZHKVFCRAFM-HNNXBMFYSA-N 0.000 claims description 2
- OOBNMPQXQXCPBF-UHFFFAOYSA-N N-[5-fluoro-2-[3-(hydroxymethyl)morpholin-4-yl]phenyl]-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound C1(=CC(=CC=C1N1C(COCC1)CO)F)NC(=O)C1=CC=NC(=N1)C1=C(F)C=CC=C1OC OOBNMPQXQXCPBF-UHFFFAOYSA-N 0.000 claims description 2
- NAXWLXJDZBNCQG-IRJFHVNHSA-N N[C@@H]1CC[C@H](CC1)C1=C(C=CC(=C1)C1=C(C=NN1C)C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F Chemical compound N[C@@H]1CC[C@H](CC1)C1=C(C=CC(=C1)C1=C(C=NN1C)C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F NAXWLXJDZBNCQG-IRJFHVNHSA-N 0.000 claims description 2
- PRBXACPKTPJDIW-XGAFWQRZSA-N N[C@@H]1CC[C@H](CC1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F Chemical compound N[C@@H]1CC[C@H](CC1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F PRBXACPKTPJDIW-XGAFWQRZSA-N 0.000 claims description 2
- PRBXACPKTPJDIW-RVWIWJKTSA-N N[C@H]1CC[C@H](CC1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F Chemical compound N[C@H]1CC[C@H](CC1)C1=C(C=CC(=C1)C=1C=NC=CC=1C#N)NC(=O)C1=NC(=NC=C1)C1=C(C=CC=C1OC)F PRBXACPKTPJDIW-RVWIWJKTSA-N 0.000 claims description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 4
- 125000005529 alkyleneoxy group Chemical group 0.000 claims 2
- VNRCXZBQRIAHFW-UHFFFAOYSA-N 2-(methoxymethyl)azetidine Chemical compound COCC1CCN1 VNRCXZBQRIAHFW-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229910052750 molybdenum Inorganic materials 0.000 claims 1
- 239000011733 molybdenum Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 description 49
- 125000004043 oxo group Chemical group O=* 0.000 description 35
- 125000000753 cycloalkyl group Chemical group 0.000 description 20
- 108010002838 hematopoietic progenitor kinase 1 Proteins 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 125000002950 monocyclic group Chemical group 0.000 description 10
- 125000003342 alkenyl group Chemical group 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 125000001188 haloalkyl group Chemical group 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- 239000011593 sulfur Substances 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 125000004438 haloalkoxy group Chemical group 0.000 description 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 3
- 230000005809 anti-tumor immunity Effects 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 108091008875 B cell receptors Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 101000573441 Homo sapiens Misshapen-like kinase 1 Proteins 0.000 description 2
- 101001059984 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 4 Proteins 0.000 description 2
- 101001059982 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 5 Proteins 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- 102100026287 Misshapen-like kinase 1 Human genes 0.000 description 2
- 102100028192 Mitogen-activated protein kinase kinase kinase kinase 2 Human genes 0.000 description 2
- 102100028193 Mitogen-activated protein kinase kinase kinase kinase 3 Human genes 0.000 description 2
- 102100028194 Mitogen-activated protein kinase kinase kinase kinase 4 Human genes 0.000 description 2
- 102100028195 Mitogen-activated protein kinase kinase kinase kinase 5 Human genes 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- SSNMISUJOQAFRR-UHFFFAOYSA-N 2,6-naphthyridine Chemical compound N1=CC=C2C=NC=CC2=C1 SSNMISUJOQAFRR-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 101710155270 Glycerate 2-kinase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001059990 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 1
- 101001059989 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 3 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101710144533 Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 1
- 101710144521 Mitogen-activated protein kinase kinase kinase kinase 3 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000000815 N-oxide group Chemical group 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229910021386 carbon form Inorganic materials 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical group O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 125000005482 norpinyl group Chemical group 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004089 sulfido group Chemical group [S-]* 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862632702P | 2018-02-20 | 2018-02-20 | |
| US62/632,702 | 2018-02-20 | ||
| US201862672772P | 2018-05-17 | 2018-05-17 | |
| US62/672,772 | 2018-05-17 | ||
| US201862750371P | 2018-10-25 | 2018-10-25 | |
| US62/750,371 | 2018-10-25 | ||
| PCT/US2019/018608 WO2019164846A1 (en) | 2018-02-20 | 2019-02-19 | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515033A JP2021515033A (ja) | 2021-06-17 |
| JP2021515033A5 JP2021515033A5 (enExample) | 2022-02-22 |
| JP7526673B2 true JP7526673B2 (ja) | 2024-08-01 |
Family
ID=65635851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566534A Active JP7526673B2 (ja) | 2018-02-20 | 2019-02-19 | がんを治療するためのｈｐｋ１阻害剤としてのｎ－（フェニル）－２－（フェニル）ピリミジン－４－カルボキサミド誘導体及び関連化合物 |
Country Status (32)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| CN115819417A (zh) | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| EP3755703B1 (en) | 2018-02-20 | 2022-05-04 | Incyte Corporation | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| JP2022513967A (ja) * | 2018-12-20 | 2022-02-09 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド |
| AU2019401495B2 (en) | 2018-12-20 | 2025-06-26 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| JP7686559B2 (ja) | 2018-12-20 | 2025-06-02 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤 |
| BR112021016522A2 (pt) | 2019-02-22 | 2021-10-26 | Hanmi Pharm. Co., Ltd. | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| EA202290154A1 (ru) | 2019-06-27 | 2022-03-29 | Ханми Фарм. Ко., Лтд. | Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты |
| EP4007638A1 (en) | 2019-08-02 | 2022-06-08 | Amgen Inc. | Pyridine derivatives as kif18a inhibitors |
| EP4007753B1 (en) | 2019-08-02 | 2025-09-24 | Amgen Inc. | Kif18a inhibitors |
| BR112022002059A2 (pt) | 2019-08-06 | 2022-06-07 | Incyte Corp | Formas sólidas de um inibidor de hpk1 |
| WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
| CN114181257B (zh) * | 2020-09-14 | 2025-02-14 | 四川科伦博泰生物医药股份有限公司 | 吡啶类化合物，包含其的药物组合物，其制备方法及其用途 |
| US20240174683A1 (en) | 2021-02-05 | 2024-05-30 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
| TW202321239A (zh) | 2021-07-20 | 2023-06-01 | 瑞典商阿斯特捷利康公司 | 作為ｈｐｋ１抑制劑用於治療癌症之經取代的吡𠯤—２—甲醯胺 |
| JP2024528722A (ja) * | 2021-07-30 | 2024-07-30 | ベイジーン リミテッド | ＨＰＫ１分解誘導薬としてのピロロ［２，３－ｂ］ピラジン系の二官能性化合物及びその使用 |
| JP2025502358A (ja) * | 2022-01-12 | 2025-01-24 | シェンゼン イオノヴァ ライフ サイエンス カンパニー リミテッド | Ｈｐｋ１阻害剤としてのヘテロアリール化合物およびその使用方法 |
| CN117510400B (zh) * | 2023-11-29 | 2026-02-06 | 山西永津集团有限公司 | 一种6-溴-2-氯-3-硝基吡啶的制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010520228A (ja) | 2007-03-01 | 2010-06-10 | ノバルティス アーゲー | Ｐｉｍキナーゼ阻害剤およびその使用方法 |
| JP2010533716A (ja) | 2007-07-19 | 2010-10-28 | シェーリング コーポレイション | プロテインキナーゼ阻害剤としての複素環アミド化合物 |
| WO2012151567A1 (en) | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
| WO2016205942A1 (en) | 2015-06-25 | 2016-12-29 | University Health Network | Hpk1 inhibitors and methods of using same |
| WO2018049152A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
Family Cites Families (245)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8800613D0 (sv) | 1988-02-23 | 1988-02-23 | Wallac Oy | A novel spectrofluorometric method and compounds that are of value for the method |
| JPH03287584A (ja) | 1990-04-05 | 1991-12-18 | Banyu Pharmaceut Co Ltd | 置換アリルアミン誘導体 |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| US6200980B1 (en) | 1995-06-07 | 2001-03-13 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl purinone derivatives |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| DE19622270A1 (de) | 1996-06-03 | 1997-12-04 | Basf Ag | Pyrimidin-4-carbonsäureamide |
| US6723719B1 (en) | 1997-04-25 | 2004-04-20 | Pfizer Inc | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction |
| RS50011B (sr) | 1998-04-20 | 2008-09-29 | Pfizer Inc., | Derivati piridin-3-karboksilne kiseline i njihova upotreba kao intermedijera |
| JP2000038350A (ja) | 1998-05-18 | 2000-02-08 | Yoshitomi Pharmaceut Ind Ltd | 糖尿病治療薬 |
| GB9823102D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
| GB9823101D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
| WO2001046124A1 (en) | 1999-12-22 | 2001-06-28 | Nihon Nohyaku Co., Ltd. | Aromatic diamide derivatives, chemicals for agricultural or horticultural use and usage thereof |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| IN187433B (enExample) | 1999-09-10 | 2002-04-27 | Cipla Ltd | |
| WO2001019827A1 (en) | 1999-09-13 | 2001-03-22 | Cipla Ltd. | A novel process for the synthesis of sildenafil citrate |
| MXPA02002938A (es) | 1999-09-17 | 2004-12-06 | Abbott Gmbh & Co Kg | Inhibidores de cinasa como agentes agentes terapeuticos. |
| ES2239035T3 (es) | 1999-09-24 | 2005-09-16 | Nihon Nohyaku Co., Ltd. | Derivados de diamida aromatica o sales de estos derivados, productos quimicos para la agricultura/horticultura y procedimiento de utilizacion de estos productos. |
| TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| HK1049834A1 (zh) | 1999-10-11 | 2003-05-30 | 辉瑞大药厂 | 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物 |
| IL139073A0 (en) | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
| CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
| US20020013327A1 (en) | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| AU2001277621A1 (en) | 2000-08-09 | 2002-03-04 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
| AU2001284417A1 (en) | 2000-09-05 | 2002-03-22 | Taisho Pharmaceutical Co. Ltd. | Hair growth stimulants |
| US6548508B2 (en) | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
| AU2002222293A1 (en) | 2000-12-19 | 2002-07-01 | Smithkline Beecham P.L.C. | Pyrazolo(3,4-c)pyridines as gsk-3 inhibitors |
| EP1343506A1 (de) | 2000-12-19 | 2003-09-17 | MERCK PATENT GmbH | Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate |
| US6784185B2 (en) | 2001-03-16 | 2004-08-31 | Pfizer Inc. | Pharmaceutically active compounds |
| US6770645B2 (en) | 2001-03-16 | 2004-08-03 | Pfizer Inc. | Pharmaceutically active compounds |
| US7902179B2 (en) | 2001-04-26 | 2011-03-08 | Ajinomoto Co., Inc. | Heterocyclic compounds |
| US20040157866A1 (en) | 2001-04-30 | 2004-08-12 | Hisashi Takasugi | Amide compounds |
| FR2825706B1 (fr) | 2001-06-06 | 2003-12-12 | Pf Medicament | Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase |
| JP2005508978A (ja) | 2001-11-02 | 2005-04-07 | ファイザー・プロダクツ・インク | Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療 |
| TW200303201A (en) | 2001-12-10 | 2003-09-01 | Bristol Myers Squibb Co | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones |
| US7166293B2 (en) | 2002-03-29 | 2007-01-23 | Carlsbad Technology, Inc. | Angiogenesis inhibitors |
| US20050119278A1 (en) | 2002-05-16 | 2005-06-02 | Che-Ming Teng | Anti-angiogenesis methods |
| US7429609B2 (en) | 2002-05-31 | 2008-09-30 | Eisai R & D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
| WO2004074286A1 (en) | 2003-02-14 | 2004-09-02 | Wyeth | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| EP1606289B1 (en) | 2003-02-14 | 2009-12-02 | Glaxo Group Limited | Carboxamide derivatives |
| EP1613747A1 (en) | 2003-03-31 | 2006-01-11 | Pfizer Products Inc. | Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof |
| OA13050A (en) | 2003-04-29 | 2006-11-10 | Pfizer Ltd | 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension. |
| EP1628661A2 (en) | 2003-06-05 | 2006-03-01 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
| CA2528587A1 (en) | 2003-06-10 | 2005-01-20 | Fulcrum Pharmaceuticals, Inc. | .beta.-lactamase inhibitors and methods of use thereof |
| ZA200305330B (en) | 2003-07-10 | 2004-05-26 | Jb Chemicals & Pharmaceuticals | An improved process for the preparation of 5-[2-ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazole[4,3-D]P yrimidin-7-one. |
| JP2007500700A (ja) | 2003-07-29 | 2007-01-18 | スミスクライン ビーチャム コーポレーション | 化合物 |
| TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| CN1905873A (zh) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| US20050137398A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-Quinuclidinyl heteroatom bridged biaryl derivatives |
| US7241773B2 (en) | 2003-12-22 | 2007-07-10 | Abbott Laboratories | 3-quinuclidinyl heteroatom bridged biaryl derivatives |
| GB0402137D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| DE102004005172A1 (de) | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase |
| CN1934111A (zh) | 2004-02-27 | 2007-03-21 | 霍夫曼-拉罗奇有限公司 | 杂芳基稠合的吡唑并衍生物 |
| WO2005085249A1 (en) | 2004-02-27 | 2005-09-15 | F. Hoffmann-La Roche Ag | Fused derivatives of pyrazole |
| JP2007526324A (ja) | 2004-03-02 | 2007-09-13 | スミスクライン・ビーチャム・コーポレイション | Ａｋｔ活性のある阻害剤 |
| TW200618800A (en) | 2004-08-03 | 2006-06-16 | Uriach Y Compania S A J | Heterocyclic compounds |
| ES2377430T3 (es) | 2004-09-02 | 2012-03-27 | Genentech, Inc. | Inhibidores piridílicos de la señalización de hedgehog |
| WO2006038001A1 (en) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
| WO2006045010A2 (en) | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| AR051596A1 (es) | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| EP1805136A1 (en) | 2004-10-28 | 2007-07-11 | The Institutes for Pharmaceutical Discovery, LLC | Substituted phenylalkanoic acids |
| AU2005304473A1 (en) | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
| WO2006053227A2 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
| TW200628463A (en) | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | Heteroaryl compounds |
| DE102004054666A1 (de) | 2004-11-12 | 2006-05-18 | Bayer Cropscience Gmbh | Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| CN100516049C (zh) | 2004-11-16 | 2009-07-22 | 永信药品工业股份有限公司 | 抗血管生成药n2-(取代的芳基甲基)-3-(取代的苯基)吲唑的合成 |
| EP1838320B1 (en) | 2005-01-07 | 2014-07-16 | Emory University | Cxcr4 antagonists for the treatment of medical disorders |
| JP5023054B2 (ja) | 2005-03-31 | 2012-09-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗バクテリア剤としての二環式ピラゾール化合物 |
| US20070032493A1 (en) | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
| EP1910369A1 (en) | 2005-07-29 | 2008-04-16 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
| DK1910384T3 (da) | 2005-08-04 | 2012-12-17 | Sirtris Pharmaceuticals Inc | Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser |
| GB0516703D0 (en) | 2005-08-15 | 2005-09-21 | Syngenta Participations Ag | Novel insecticides |
| JP2007055940A (ja) | 2005-08-24 | 2007-03-08 | Astellas Pharma Inc | ピラゾロピリミジン誘導体 |
| CN101243051A (zh) | 2005-08-25 | 2008-08-13 | 霍夫曼-拉罗奇有限公司 | p38 MAP激酶抑制剂及使用它的方法 |
| BRPI0614884A2 (pt) | 2005-08-25 | 2011-04-19 | Hoffmann La Roche | inibidores de p38 map cinase e métodos para uso dos mesmos |
| KR101011956B1 (ko) | 2005-08-25 | 2011-01-31 | 에프. 호프만-라 로슈 아게 | Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법 |
| CN101277939A (zh) | 2005-09-09 | 2008-10-01 | 布里斯托尔-迈尔斯斯奎布公司 | 无环ikur抑制剂 |
| US20070087988A1 (en) | 2005-09-30 | 2007-04-19 | New York University | Hematopoietic progenitor kinase 1 for modulation of an immune response |
| EP1940296A2 (en) | 2005-10-25 | 2008-07-09 | SmithKline Beecham Corporation | Chemical compounds |
| AU2006311766A1 (en) | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Indole compounds having C4-acidic substituents and use thereof as phospholipase-A2 inhibitors |
| CA2629964A1 (en) | 2005-11-30 | 2007-06-07 | Astellas Pharma Inc. | 2-aminobenzamide derivative |
| GB0525143D0 (en) | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| EP1979325A1 (en) | 2006-01-11 | 2008-10-15 | AstraZeneca AB | Morpholino pyrimidine derivatives and their use in therapy |
| US8658801B2 (en) | 2006-02-16 | 2014-02-25 | Syngenta Crop Protection, Llc | Pesticides containing a bicyclic bisamide structure |
| AU2007230911A1 (en) | 2006-03-23 | 2007-10-04 | Synta Pharmaceuticals Corp. | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses |
| WO2007120454A1 (en) | 2006-03-30 | 2007-10-25 | Irm Llc | Azolopyrimidines as inhibitors of cannabinoid 1 activity |
| PL2018380T3 (pl) | 2006-05-19 | 2012-05-31 | Abbvie Bahamas Ltd | Skondensowane azabicykliczne pochodne alkanowe podstawione bicykloheterocyklem o aktywności wobec OUN |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| GB0614691D0 (en) | 2006-07-24 | 2006-08-30 | Syngenta Participations Ag | Insecticidal compounds |
| JP2010505859A (ja) | 2006-10-06 | 2010-02-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤およびそれを使用するための方法 |
| WO2008070313A2 (en) | 2006-10-20 | 2008-06-12 | Concert Pharmaceuticals Inc. | 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use |
| US20080194557A1 (en) | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
| WO2008089310A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of obesity |
| US20140249135A1 (en) * | 2007-03-01 | 2014-09-04 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| CL2008001822A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| MY146643A (en) | 2007-07-30 | 2012-09-14 | Dae Woong Pharma | Novel benzoimidazole derivatives and pharmaceutical composition comprising the same |
| CN101790519B (zh) | 2007-08-08 | 2013-10-16 | 默克雪兰诺有限公司 | 用于治疗多发性硬化症的结合于鞘氨醇1-磷酸(s1p)的6-氨基-嘧啶-4-羧酰胺衍生物及相关化合物 |
| GB0716414D0 (en) | 2007-08-22 | 2007-10-03 | Syngenta Participations Ag | Novel insecticides |
| WO2009032651A1 (en) | 2007-08-31 | 2009-03-12 | Smithkline Beecham Corporation | Inhibitors of akt activity |
| WO2009038784A1 (en) | 2007-09-21 | 2009-03-26 | Amgen Inc. | Triazole fused heteroaryl compounds as p38 kinase inhibitors |
| WO2009058348A1 (en) | 2007-11-01 | 2009-05-07 | Sirtris Pharmaceuticals, Inc. | Amide derivatives as sirtuin modulators |
| KR100963644B1 (ko) | 2007-11-23 | 2010-06-15 | 한국과학기술연구원 | 피라졸로피리미딘온 유도체 및 그의 제조방법 |
| CA2714181C (en) | 2008-02-04 | 2013-12-24 | Mercury Therapeutics, Inc. | Ampk modulators |
| CN102098918A (zh) | 2008-05-13 | 2011-06-15 | 帕纳德制药公司 | 用于治疗癌症和神经退行性疾病的生物活性化合物 |
| CN102089278A (zh) | 2008-06-11 | 2011-06-08 | Irm责任有限公司 | 用于治疗疟疾的化合物和组合物 |
| NZ603525A (en) | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| WO2010029300A1 (en) | 2008-09-12 | 2010-03-18 | Biolipox Ab | Bis aromatic compounds for use in the treatment of inflammation |
| EP2166008A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| WO2010046780A2 (en) | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| WO2010080503A1 (en) | 2008-12-19 | 2010-07-15 | Genentech, Inc. | Heterocyclic compounds and methods of use |
| KR20100101055A (ko) | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동 관련 질환의 치료 또는 예방용 약학적 조성물 |
| WO2010107768A1 (en) | 2009-03-18 | 2010-09-23 | Schering Corporation | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
| EP2411328B1 (en) | 2009-03-26 | 2019-07-24 | Northeastern University | Carbon nanostructures from pyrolysis of organic materials |
| WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| US8846673B2 (en) | 2009-08-11 | 2014-09-30 | Bristol-Myers Squibb Company | Azaindazoles as kinase inhibitors and use thereof |
| EP2477498A4 (en) | 2009-09-14 | 2013-02-27 | Merck Sharp & Dohme | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| ES2360333B1 (es) | 2009-10-29 | 2012-05-04 | Consejo Superior De Investigaciones Cientificas (Csic) (70%) | Derivados de bis (aralquil) amino y sistemas (hetero) aromaticos de seis miembros y su uso en el tratamiento de patologias neurodegenerativas, incluida la enfermedad de alzheimer |
| JP2013032290A (ja) | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
| WO2011078143A1 (ja) | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
| WO2011079236A1 (en) | 2009-12-22 | 2011-06-30 | The Ohio State University Research Foundation | Compositions and methods for cancer detection and treatment |
| WO2011090738A2 (en) | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| US20130109758A1 (en) | 2010-01-06 | 2013-05-02 | The University Of British Columbia | Bisphenol derivative therapeutics and methods for their use |
| DE102010009903A1 (de) | 2010-03-02 | 2011-09-08 | Merck Patent Gmbh | Verbindungen für elektronische Vorrichtungen |
| CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| JP6112486B2 (ja) | 2010-04-27 | 2017-04-12 | カルシメディカ，インク． | 細胞内カルシウムを調節する化合物 |
| KR20110123657A (ko) | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| GB201008134D0 (en) | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
| JP2011246389A (ja) | 2010-05-26 | 2011-12-08 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体 |
| JP2013528169A (ja) | 2010-05-27 | 2013-07-08 | バイエル・クロップサイエンス・アーゲー | 殺菌剤としてのピリジニルカルボン酸誘導体 |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| CN103068814B (zh) | 2010-06-15 | 2015-11-25 | 拜耳知识产权有限责任公司 | 邻氨基苯甲酸衍生物 |
| EP2582666B1 (en) | 2010-06-16 | 2014-08-13 | Purdue Pharma L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
| CA2806655A1 (en) | 2010-07-28 | 2012-02-02 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-b]pyridazines |
| US10005750B2 (en) | 2010-10-06 | 2018-06-26 | J-Pharma Co., Ltd. | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action |
| GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| CA2819373A1 (en) | 2010-12-09 | 2012-06-14 | Amgen Inc. | Bicyclic compounds as pim inhibitors |
| CN103261188A (zh) | 2010-12-17 | 2013-08-21 | 先正达参股股份有限公司 | 杀虫化合物 |
| PT2661433T (pt) | 2011-01-04 | 2017-10-24 | Novartis Ag | Compostos de indole ou seus análogos úteis para o tratamento da degeneração macular relacionada com a idade (amd) |
| EP2672820B1 (en) | 2011-02-07 | 2019-04-17 | The Washington University | Mannoside compounds and methods of use thereof |
| EP2691399B1 (en) | 2011-03-28 | 2016-07-13 | F.Hoffmann-La Roche Ag | Thiazolopyrimidine compounds |
| HRP20170422T1 (hr) | 2011-04-12 | 2017-06-16 | Chong Kun Dang Pharmaceutical Corp. | 3-(2-aril-cikloalkenilmetil)-oksazolidin-2-on derivati kao inhibitori transportnog proteina estera kolesterola (cetp) |
| AP2013007253A0 (en) | 2011-04-21 | 2013-11-30 | Origenis Gmbh | Pyrazolo [4,3-D] pyrimidines useful as kinase inhibitors |
| US20140288069A1 (en) | 2011-05-17 | 2014-09-25 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines as mknk1 kinase inhibitors |
| US20140107151A1 (en) | 2011-05-17 | 2014-04-17 | Principia Biophama Inc. | Tyrosine kinase inhibitors |
| TW201311677A (zh) | 2011-05-31 | 2013-03-16 | Syngenta Participations Ag | 殺蟲化合物 |
| WO2012163942A1 (en) | 2011-06-01 | 2012-12-06 | Bayer Intellectual Property Gmbh | Substituted aminoimidazopyridazines |
| WO2012175591A1 (en) | 2011-06-22 | 2012-12-27 | Bayer Intellectual Property Gmbh | Heterocyclyl aminoimidazopyridazines |
| EP3111937B1 (en) | 2011-07-08 | 2020-06-17 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for treatment of liver cancer |
| EP2543372A1 (en) | 2011-07-08 | 2013-01-09 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for the treatment of liver cancer |
| AU2012293417A1 (en) | 2011-08-10 | 2013-05-02 | Purdue Pharma L.P. | TRPV1 antagonists including dihydroxy substituent and uses thereof |
| EP2742046A1 (en) | 2011-08-12 | 2014-06-18 | F.Hoffmann-La Roche Ag | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE |
| KR20140047160A (ko) | 2011-08-12 | 2014-04-21 | 에프. 호프만-라 로슈 아게 | 인다졸 화합물, 조성물 및 사용 방법 |
| WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| CA2849345A1 (en) | 2011-09-23 | 2013-03-28 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| CN102503959B (zh) | 2011-10-25 | 2015-04-08 | 南方医科大学 | 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用 |
| CN102516263B (zh) | 2011-10-25 | 2015-04-08 | 南方医科大学 | 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用 |
| KR20140095513A (ko) | 2011-11-01 | 2014-08-01 | 에프. 호프만-라 로슈 아게 | 이미다조피리다진 화합물 |
| AP3675A (en) | 2012-02-17 | 2016-04-15 | Kineta Four Llc | Antiviral drugs for treatment of arenavirus infection |
| TW201348231A (zh) | 2012-02-29 | 2013-12-01 | Amgen Inc | 雜雙環化合物 |
| KR20140131955A (ko) | 2012-03-09 | 2014-11-14 | 카나 바이오사이언스 인코포레이션 | 신규 트리아진 유도체 |
| JP6101248B2 (ja) | 2012-03-28 | 2017-03-22 | 出光興産株式会社 | 新規化合物、有機エレクトロルミネッセンス素子用材料および有機エレクトロルミネッセンス素子 |
| UY34750A (es) | 2012-04-20 | 2013-11-29 | Gilead Sciences Inc | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. |
| WO2014003405A1 (ko) | 2012-06-26 | 2014-01-03 | 주식회사 제이앤드제이 캐미칼 | 신규한 화합물 및 이를 포함하는 발광소자 |
| MX2014015738A (es) | 2012-06-28 | 2015-08-06 | Novartis Ag | Derivados de pirrolidina y su uso como moduladores de la senda del complemento. |
| KR101936851B1 (ko) | 2012-07-16 | 2019-01-11 | 한국과학기술연구원 | 단백질 키나아제 저해제인 신규 피라졸로피리딘 유도체 또는 인다졸 유도체 |
| WO2014024125A1 (en) | 2012-08-08 | 2014-02-13 | Celon Pharma S.A. | Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors |
| TW201412744A (zh) | 2012-08-23 | 2014-04-01 | Mitsubishi Tanabe Pharma Corp | 吡唑并嘧啶化合物 |
| US9882150B2 (en) | 2012-09-24 | 2018-01-30 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Metal compounds, methods, and uses thereof |
| WO2014055955A1 (en) | 2012-10-05 | 2014-04-10 | Rigel Pharmaceuticals, Inc. | Gdf-8 inhibitors |
| DK2935222T3 (en) | 2012-12-21 | 2019-01-07 | Epizyme Inc | PRMT5 INHIBITORS AND APPLICATIONS THEREOF |
| KR102137472B1 (ko) | 2013-02-08 | 2020-07-27 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| EP3495357B1 (en) | 2013-03-14 | 2021-05-05 | The Trustees of Columbia University in the City of New York | 4-phenylpiperidines, their preparation and use |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| MX353412B (es) | 2013-04-03 | 2018-01-10 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| US9034927B2 (en) | 2013-05-22 | 2015-05-19 | Curza Global, Llc | Methods of use for compositions comprising a biocidal polyamine |
| CN104232076B (zh) | 2013-06-10 | 2019-01-15 | 代表亚利桑那大学的亚利桑那校董会 | 具有改进的发射光谱的磷光四齿金属络合物 |
| US9718818B2 (en) | 2013-08-22 | 2017-08-01 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
| WO2015037965A1 (en) | 2013-09-16 | 2015-03-19 | Rohm And Haas Electronic Materials Korea Ltd. | Novel organic electroluminescent compounds and organic electroluminescent device comprising the same |
| CA2927924A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| BR112016008632A8 (pt) | 2013-10-21 | 2020-03-17 | Merck Patent Gmbh | compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica |
| EP3444251B1 (en) | 2013-12-11 | 2023-06-07 | Biogen MA Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| EP3079683A4 (en) | 2013-12-13 | 2017-12-20 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| EP3083589B1 (en) | 2013-12-20 | 2019-12-18 | Sunshine Lake Pharma Co., Ltd. | Substituted piperazine compounds and methods of use thereof |
| EP3092226B1 (en) | 2014-01-10 | 2019-03-13 | Aurigene Discovery Technologies Limited | Indazole compounds as irak4 inhibitors |
| JP6640098B2 (ja) | 2014-02-05 | 2020-02-05 | メルク、パテント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ ＧｍｂＨ | 金属錯体 |
| US9732103B2 (en) | 2014-02-25 | 2017-08-15 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders |
| US9871208B2 (en) | 2014-02-26 | 2018-01-16 | Samsung Display Co., Ltd. | Condensed cyclic compound and organic light-emitting device including the same |
| WO2015164956A1 (en) | 2014-04-29 | 2015-11-05 | The University Of British Columbia | Benzisothiazole derivative compounds as therapeutics and methods for their use |
| US20150328188A1 (en) | 2014-05-19 | 2015-11-19 | Everardus O. Orlemans | Combination Therapies for the Treatment of Proliferative Disorders |
| KR102402729B1 (ko) | 2014-06-18 | 2022-05-26 | 메르크 파텐트 게엠베하 | 유기 전계발광 소자용 재료 |
| WO2015193506A1 (en) | 2014-06-20 | 2015-12-23 | Institut Pasteur Korea | Anti-infective compounds |
| AU2015275730A1 (en) | 2014-06-20 | 2016-12-15 | Aurigene Discovery Technologies Limited | Substituted indazole compounds as IRAK4 inhibitors |
| US20170198006A1 (en) | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2015200682A1 (en) | 2014-06-25 | 2015-12-30 | Vanderbilt University | Substituted 4-alkoxypicolinamide analogs ds mglur5 negative allosteric modulators |
| KR20160007967A (ko) | 2014-07-10 | 2016-01-21 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| WO2016040188A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016041618A1 (en) | 2014-09-15 | 2016-03-24 | Merck Patent Gmbh | Substituted indazoles and related heterocycles |
| US10253023B2 (en) | 2014-10-06 | 2019-04-09 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| CN107206088A (zh) | 2014-12-05 | 2017-09-26 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物 |
| WO2016124304A1 (de) | 2015-02-03 | 2016-08-11 | Merck Patent Gmbh | Metallkomplexe |
| EP3265445B1 (en) | 2015-03-06 | 2021-05-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| CN112679467B (zh) | 2015-03-11 | 2024-11-01 | Fmc公司 | 杂环取代的二环唑杀有害生物剂 |
| WO2016161571A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Indazole and azaindazole btk inhibitors |
| TW201701879A (zh) | 2015-04-30 | 2017-01-16 | 拜耳製藥公司 | Ｉｒａｋ４抑制劑組合 |
| JP2018524372A (ja) | 2015-07-15 | 2018-08-30 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物 |
| CN108024971A (zh) | 2015-07-15 | 2018-05-11 | 奥列基因发现技术有限公司 | 作为irak-4抑制剂的取代的氮杂化合物 |
| WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017023894A1 (en) | 2015-08-03 | 2017-02-09 | Raze Therapeutics, Inc. | Mthfd2 inhibitors and uses thereof |
| CA2995094A1 (en) | 2015-08-07 | 2017-02-16 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
| WO2017045955A1 (en) | 2015-09-14 | 2017-03-23 | Basf Se | Heterobicyclic compounds |
| EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017108744A1 (de) | 2015-12-22 | 2017-06-29 | Bayer Pharma Aktiengesellschaft | Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| TWI726968B (zh) | 2016-01-07 | 2021-05-11 | 開曼群島商Ｃｓ醫藥技術公司 | Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑 |
| JP6680953B2 (ja) | 2016-07-19 | 2020-04-15 | アーサー バーナード カミングス | 人工調節型レンズ複合体 |
| EP3492462B1 (en) | 2016-07-26 | 2023-08-30 | Shenzhen TargetRx, Inc. | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
| CN115819417A (zh) | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| EP3755703B1 (en) | 2018-02-20 | 2022-05-04 | Incyte Corporation | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| GEP20227433B (en) | 2018-04-26 | 2022-10-25 | Pfizer | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| US11633459B2 (en) | 2018-05-04 | 2023-04-25 | Novo Nordisk A/S | GIP derivatives and uses thereof |
| EP3793559A1 (en) | 2018-05-17 | 2021-03-24 | Bayer Aktiengesellschaft | Substituted dihydropyrazolo pyrazine carboxamide derivatives |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| BR112022002059A2 (pt) | 2019-08-06 | 2022-06-07 | Incyte Corp | Formas sólidas de um inibidor de hpk1 |
-
2019
- 2019-02-19 EP EP19708757.0A patent/EP3755703B1/en active Active
- 2019-02-19 LT LTEPPCT/US2019/018608T patent/LT3755703T/lt unknown
- 2019-02-19 DK DK19708757.0T patent/DK3755703T3/da active
- 2019-02-19 JP JP2020566534A patent/JP7526673B2/ja active Active
- 2019-02-19 CR CR20200421A patent/CR20200421A/es unknown
- 2019-02-19 BR BR112020016927-7A patent/BR112020016927A2/pt not_active IP Right Cessation
- 2019-02-19 HR HRP20220833TT patent/HRP20220833T1/hr unknown
- 2019-02-19 KR KR1020207027017A patent/KR20200133747A/ko active Pending
- 2019-02-19 HU HUE19708757A patent/HUE059624T2/hu unknown
- 2019-02-19 WO PCT/US2019/018608 patent/WO2019164846A1/en not_active Ceased
- 2019-02-19 MD MDE20210010T patent/MD3755703T2/ro unknown
- 2019-02-19 IL IL276779A patent/IL276779B2/en unknown
- 2019-02-19 RS RS20220715A patent/RS63659B1/sr unknown
- 2019-02-19 SM SM20220294T patent/SMT202200294T1/it unknown
- 2019-02-19 PT PT197087570T patent/PT3755703T/pt unknown
- 2019-02-19 SI SI201930287T patent/SI3755703T1/sl unknown
- 2019-02-19 CA CA3091517A patent/CA3091517A1/en active Pending
- 2019-02-19 PL PL19708757.0T patent/PL3755703T3/pl unknown
- 2019-02-19 ES ES19708757T patent/ES2922237T3/es active Active
- 2019-02-19 US US16/278,865 patent/US10800761B2/en active Active
- 2019-02-19 CN CN201980020899.4A patent/CN112292380B/zh not_active Expired - Fee Related
- 2019-02-19 AU AU2019223955A patent/AU2019223955B2/en not_active Ceased
- 2019-02-19 UA UAA202005974A patent/UA128286C2/uk unknown
- 2019-02-19 MX MX2020008656A patent/MX2020008656A/es unknown
- 2019-02-19 PE PE2020001252A patent/PE20210397A1/es unknown
- 2019-02-19 SG SG11202007917VA patent/SG11202007917VA/en unknown
- 2019-02-20 TW TW108105529A patent/TWI828653B/zh not_active IP Right Cessation
-
2020
- 2020-08-19 PH PH12020551278A patent/PH12020551278A1/en unknown
- 2020-08-19 CL CL2020002146A patent/CL2020002146A1/es unknown
- 2020-09-09 US US17/015,797 patent/US11731958B2/en active Active
- 2020-09-18 EC ECSENADI202058964A patent/ECSP20058964A/es unknown
- 2020-09-18 CO CONC2020/0011530A patent/CO2020011530A2/es unknown
-
2022
- 2022-07-26 CY CY20221100512T patent/CY1125401T1/el unknown
-
2023
- 2023-06-21 US US18/212,444 patent/US12466815B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010520228A (ja) | 2007-03-01 | 2010-06-10 | ノバルティス アーゲー | Ｐｉｍキナーゼ阻害剤およびその使用方法 |
| JP2010533716A (ja) | 2007-07-19 | 2010-10-28 | シェーリング コーポレイション | プロテインキナーゼ阻害剤としての複素環アミド化合物 |
| WO2012151567A1 (en) | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
| WO2016205942A1 (en) | 2015-06-25 | 2016-12-29 | University Health Network | Hpk1 inhibitors and methods of using same |
| WO2018049152A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7526673B2 (ja) | がんを治療するためのｈｐｋ１阻害剤としてのｎ－（フェニル）－２－（フェニル）ピリミジン－４－カルボキサミド誘導体及び関連化合物 | |
| US11492354B2 (en) | Indazole compounds and uses thereof | |
| JP7432655B2 (ja) | Ｈｐｋ１調節薬としてのピラゾロピリジン誘導体及びがんの治療のためのその用法 | |
| US11299473B2 (en) | Benzimidazole and indole compounds and uses thereof | |
| US11866426B2 (en) | Benzothiazole compounds and uses thereof | |
| US10745388B2 (en) | Indazole compounds and uses thereof | |
| US10722495B2 (en) | Cyanoindazole compounds and uses thereof | |
| HK40042881B (en) | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer | |
| HK40042881A (en) | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer | |
| HK40010119B (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| HK40010119A (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220214 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220214 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230131 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230428 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230629 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230727 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230926 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240222 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240528 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240626 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240722 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7526673 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |